Novartis AG





Market Closed - Swiss Exchange 11:30:35 2023-12-05 am EST Intraday chart for Novartis AG 5-day change 1st Jan Change
85.06 CHF -1.25% -0.26% +1.76%
This article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Anything is possible
Key Jobs Report Awaited as Exchange-Traded Funds, Equity Futures Decline Pre-Bell Tuesday MT
NOVARTIS AG : JP Morgan remains Neutral ZD
Blackstone explores sale of Anthos Therapeutics -sources RE
Blackstone Mulling Potential Sale of Blood-Thinner Developer Anthos MT
Blackstone explores sale of Anthos Therapeutics -sources RE
NOVARTIS AG : Deutsche Bank gives a Buy rating ZD
NOVARTIS : Oddo BHF confirms its recommendation after R&D day CF
NOVARTIS AG : Sell rating from Barclays ZD
Novartis' Kymriah, Other CAR-T Cancer Therapies Under US Investigation Over Alleged Safety Issues MT
US FDA investigating safety risk of CAR-T cancer therapies RE
Health Care Down as FDA Probes Immunotherapy Treatments -- Health Care Roundup DJ
FDA Looking Into All Approved CAR T Therapies on Risk of Cancer in White Blood Cells DJ
FDA Probes T-Cell Malignancies in Patients Receiving CAR-T Cell Therapies MT
US FDA investigating safety risk of CAR-T therapies RE
Swiss Market Index Slumps Ahead of Key Inflation Reports MT
Novartis raises sales growth target RE
Transcript : Novartis AG - Special Call CI
European Midday Briefing : Stocks Struggle Again as November Rally Continues to Stall DJ
NOVARTIS AG : Gets a Neutral rating from UBS ZD
NOVARTIS : price target maintained by Oddo BHF CF
NOVARTIS AG : Jefferies reaffirms its Buy rating ZD
Novartis Touts R&D Pipeline Progress, Upgraded Midterm Targets as Pure-play Medicines Company MT
Novartis lifts sales growth target to 5% per year through 2027 RE
Novartis Raises Mid-Term Sales Growth Targets DJ
Chart Novartis AG
More charts
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by family of products as follows: - pharmaceutical products (81.7%): used to treat cardiovascular, respiratory, and dermatological diseases, gastrointestinal disorders, cancers, central nervous system disorders, hormone imbalances, etc.; - generic drugs (18.3%; Sandoz). Net sales are distributed geographically as follows: Europe (36.5%), the United States (34.9%), Asia/Africa/Australasia (20.9%), Canada and Latin America (7.7%).
More about the company
Trading Rating :
Investor Rating :
ESG Refinitiv :
More Ratings
Mean consensus
Number of Analysts
Last Close Price
Average target price
Spread / Average Target
1st Jan change Capi.
+1.76% 203 B $
+61.52% 527 B $
+46.50% 448 B $
-10.11% 382 B $
-4.24% 266 B $
-10.25% 255 B $
-13.61% 227 B $
-9.57% 201 B $
-43.14% 165 B $
+3.05% 146 B $
Other Pharmaceuticals
  1. Stock
  2. Equities
  3. Stock Novartis AG - Swiss Exchange
  4. News Novartis AG
  5. AlphaValue/Baader Europe Lifts Price Target on Novartis, Maintains Add Recommendation
The best tools reserved for subscribers to boost the performance of your investments!
Optimize my profits